Back to search
FDAFDA · Food and drugs·Recall number D-0441-2024

NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03

Published April 24, 2024 · Recall initiated: March 27, 2024

Summary

FDA records drug Class III recall D-0441-2024, published April 24, 2024 and initiated March 27, 2024. Recalling firm: Esperion; Status: Completed; Reported quantity: 3,480 30-count bottles; Lot: Lot #, 1990305, Exp 08-31-2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.

What to do

Voluntary: Firm initiated · Letter

Get an email if NEXLIZET has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NEXLIZET
Manufacturer
Esperion
Distributor
Nationwide in the USA
Lot
Lot #, 1990305, Exp 08-31-2025
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion Therapeutics, Ann Arbor, MI 48108, NDC 72426-818-03 recalled?

Yes. FDA published recall D-0441-2024 on April 24, 2024. Reported hazard: Failed dissolution specifications: out-of-specification bempedoic acid dissolution at the 0-month timepoint.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NEXLIZET.